Skip to main content
Premium Trial:

Request an Annual Quote

Danaher Offering €6.20B in Senior Notes

NEW YORK – Danaher announced Tuesday that its European subsidiary priced an offering of €6.2 billion ($6.83 billion) in senior notes due between 2026 and 2049.

The company will offer €1.25 billion of .2 percent senior notes due in 2026; €1.25 billion of .45 percent senior notes due in 2028; €1.75 billion of .75 percent senior notes due in 2031; €1.25 billion of 1.35 percent senior notes due in 2039; and €750 million of 1.8 percent senior notes due in 2049.

The Washington, DC-based conglomerate said in a statement it plans to use the money to fund part of the cash consideration and other costs associated with its planned $21.4 billion acquisition of GE Life Sciences' Biopharma business. Danaher also said it may invest the proceeds in short-term bank deposits or investment-grade securities.

The company expects the offering to close on Sept. 18, 2019.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.